Biotechnology Updates: Seattle Genetics Expands Their Collaborations

By Ray BlancoPosted March 25, 2011

There are emerging technologies in development sitting at the crossroads between traditional technology and biotechnology. With a greater ability to tailor solutions using the basic building blocks of matter, a great convergence is taking place. As these innovations become commercialized, they will present new investment opportunities.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Technology Profits Confidential

With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, Ray Blanco’s FDA Trader, Penny Pot Profits, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco

Seattle Genetics Data Seals the Deal for Advanced Hodgkin’s Lymphoma

By Ray BlancoPosted June 15, 2012

Last week, several of the cancer warriors in our portfolio presented new data on the power of their molecular wares at ASCO. Seattle Genetics (NASDAQ:SGEN) just followed up on its own presentation this week with new data for Adcetris, its lead compound. Aimed at cancer that expresses a target called CD30, Adcetris received approval from the FDA for late-stage lymphoma last year. The new data are for Adcetris used to treat relapsed or resistant Hodgkin's lymphoma in patients who have received stem cell transplants. Seventy-five percent of patients showed a positive response to therapy, while a full third showed their condition completely clearing up.

Could This COVID-19 Play Cure Brain Cancer?

By Ray BlancoPosted May 15, 2020

One position is in our portfolio thanks to the company’s work in advancing a COVID-19 fix. However, there’s a lot more going on at this small biotech — with tremendous additional value waiting to be unlocked for investors. The company’s DNA vaccine technology is applicable to far more than just the current coronavirus outbreak. In fact, it can be considered a platform for treating much more than just infectious disease.

Internet of the Future

By Ray BlancoPosted December 20, 2019

This tech company has had a tough quarter, but their future is looking bright. Especially when it comes to their hand in the 5G revolution… Get ready for some game-changing technology!

Apple’s Big Event: What Caught My Attention

By Ray BlancoPosted September 18, 2020

Apple revealed a slew of products this week. But what caught my attention weren’t these new Apple gadgets. It was services.

Vertex Races Ahead With New Hepatitis Cures

By Ray BlancoPosted February 24, 2012

The race for an all-oral hepatitis C cure continues to heat up. As you know, Vertex Pharmaceuticals made hepatitis treatment history in 2011 when Incivek became one of the two new hepatitis C therapies that were the first to be introduced in many years. To date, Incivek has dominated its competitors because of evidence of greater efficacy, and has enjoyed one of the most successful drug launches in history.

Tech Reaching New Highs – These Two Stocks Are Buys

By Ray BlancoPosted March 9, 2018

Despite the strong market sell off, the tech sector is again in record-setting territory. We’re at a technology inflection point, where the chips, the sensors, and the software are all becoming good enough to create value in ways we’ve never seen before.

Login